

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 754861501 US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: Nov. 14, 2005

Signature: *Bonnie Crespi*

(Bonnie Crespi)

Docket No.: 61223(50586)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Lijun Sun et al.

Application No.: 10/686,505

Confirmation No.: 3546

Filed: October 14, 2003

Art Unit: 1626

For: NOVEL COMPOUNDS

Examiner: Nolan, J.M.

**RESPONSE TO RESTRICTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Applicants are in receipt of the Restriction Requirement mailed on August 11, 2005 in the above-referenced patent application. A request for extension of time to and including November 14, 2005 (each of November 11-13, 2005, being a Federal holiday, Saturday or Sunday) accompanies this paper.

Applicants respectfully request reconsideration of the Restriction Requirement on the grounds that consideration and examination of the groups specified in the Restriction should not impose an undue burden.

Additionally, significant expense and time would be saved if all of the groups (i.e., all pending claims) were searched and examined at this time.

Nonetheless, to provide a complete response, Applicants elect with traverse the claims of Group I, claims 1-25, drawn to compounds or compositions according to the formula of claim 1, as defined in the Office Communication.

Moreover, the Examiner has required that Applicants select a single compound. Solely for compliance with the Office Communication, Applicants select the compound in which:  $R_1 = m\text{-tolyl}$ ;  $R_2 = R_4 = R_5 = H$  for each occurrence;  $R_3 = 2\text{-pyridin-2-yloxy}$ ;  $A = NH$ ;  $B = N$ ;  $X = NH$ ;  $Y = O$ ;  $Z = N$ ;  $W = O$ ; and  $n = 2$ . For the Examiner's convenience, this is the compound {6-morpholin-4-yl-2-[2-pyridin-2-yloxy]-ethoxy}-9H-purin-8-yl}-*m*-tolyl-amine, disclosed in Example 1 of the specification.

The election of Group I and the single compound is being made solely to comply with the Restriction Requirement and the right to file divisional applications on non-elected subject matter is reserved.

The Examiner has indicated that withdrawn process claims containing all the limitations of an allowable product claim will be rejoined pursuant to MPEP 821.04. Applicants further respectfully request that rejoinder of all groups be considered by the Examiner following the search.

Early and favorable consideration of the application is earnestly solicited.

Although it is believed that no further extension of time is required, Applicants conditionally petition for an necessary extension of time. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 61223(50586).

Dated: November 14, 2005

Respectfully submitted,

By   
Mark D. Russett

Registration No.: 41,281  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 439-4444  
Attorneys/Agents for Applicant